<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936857</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA037441_VNE</org_study_id>
    <secondary_id>1R01DA037441</secondary_id>
    <nct_id>NCT01936857</nct_id>
  </id_info>
  <brief_title>Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO)</brief_title>
  <official_title>Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanoi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minneapolis Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two models of substance abuse treatment in Vietnam,
      and how they each affect HIV care. In Vietnam, the current model for treating people with HIV
      who are also dependent on opioids is to refer them to methadone maintenance treatment
      centers. The new model the protocol will study is treatment of HIV and opioid dependence with
      buprenorphine/naloxone and counseling in the HIV clinic.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV Viral Suppression</measure>
    <time_frame>12 months</time_frame>
    <description>HIV-1 RNA &lt; 200 copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Receipt of Antiretroviral Therapy (ART)</measure>
    <time_frame>12 months</time_frame>
    <description>Initiation of and retention on treatment with antiretroviral medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in HIV care</measure>
    <time_frame>12 months</time_frame>
    <description>Attendance at scheduled HIV clinic visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heroin use</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>HIV</condition>
  <condition>Substance Related Disorders</condition>
  <arm_group>
    <arm_group_label>Buprenorphine/naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Office based treatment of opioid dependence with buprenorphine/naloxone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methadone Maintenance Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Referral to methadone maintenance therapy for treatment of opioid dependence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
    <description>Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.</description>
    <arm_group_label>Buprenorphine/naloxone</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone Maintenance Therapy</intervention_name>
    <description>Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.</description>
    <arm_group_label>Methadone Maintenance Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive

          -  Current moderate or severe DSM-V opioid use disorder

          -  Urine drug screen positive for opioids

          -  Interested in receiving treatment for opioid dependence

          -  Age at least 18 years old

          -  Willing to practice an effective method of birth control, if female

        Exclusion Criteria:

          -  Known hypersensitivity to buprenorphine or naloxone

          -  AST &amp; ALT &gt; 5x upper limit

          -  Currently pregnant or breastfeeding

          -  Serious medical or psychiatric illness in past 30 days (e.g. opportunistic infection,
             psychosis) that precludes safe participation in the opinion of study physician

          -  Methadone maintenance treatment within 30 days of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip T Korthuis, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip T Korthuis, MD, MPH</last_name>
    <phone>503-494-8044</phone>
    <email>korthuis@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giang M Le, MD</last_name>
    <phone>84-0913281842</phone>
    <email>leminhgiang@hmu.edu.vn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bac Giang PAC OPC</name>
      <address>
        <city>Bac Giang</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dong Da OPC</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hoang Mai HIV Clinic</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Long Bien</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tu Liem</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thanh Hoa PAC OPC</name>
      <address>
        <city>Thanh Hoa</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2013</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>P. Todd Korthuis</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

